Difference between revisions of "Vindesine (Eldisine)"
Jump to navigation
Jump to search
(updated also known as) |
|||
| Line 9: | Line 9: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | *[[Non-Hodgkin lymphoma]] | + | *[[Aggressive Non-Hodgkin lymphoma]] |
==Patient drug information== | ==Patient drug information== | ||
Revision as of 17:01, 20 June 2013
Also known as desacetylvinblastine amide, DAVA, DVA, Eldesine, or VDS.
General information
Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Vindesine (Eldisine) patient information at Macmillan Cancer Support[3]
- Vindesine (Eldisine) patient information at Genus Pharmaceuticals[4]
- Vindesine (Eldisine) patient drug information (UpToDate)[5]
References
- ↑ 1.0 1.1 Vindesine (Eldisine) package insert
- ↑ Vindesine (Eldisine) package insert (locally hosted backup)
- ↑ Vindesine (Eldisine) patient information at Macmillan Cancer Support
- ↑ Vindesine (Eldisine) patient information at Genus Pharmaceuticals
- ↑ Vindesine (Eldisine) patient drug information (UpToDate)